Progress in tests and treatments for Alzheimer disease

March 10, 2023



Sevigny Nature 2016

Knight ADRC
Alzheimer's Disease Research Center
WASHINGTON UNIVERSITY ST. LOUIS

Suzanne E. Schindler, MD, PhD
Associate Professor of Neurology

Washington University in St. Louis
SCHOOL OF MEDICINE

Disclosures: Suzanne Schindler, MD, PhD

- Research support/grants: Career development, salary and research support is primarily from K23AG053426 and R01AG070941
- **Dr. Schindler is analyzing biomarker data provided to Washington University by C2N Diagnostics; no financial incentives or research funding were provided to Dr. Schindler in return.**
- Stock/Equity: None
- **Consulting/Employment: Scientific advisory board on blood-based biomarkers for Eisai.**
- Speakers Bureau/Honoraria: Dr. Schindler receives honoraria as a member of the biorepository review committee for the non-profit National Centralized Repository for Alzheimer's Disease (NCRAD); she has received honoraria for participating in expert panels and reviewing grants for non-profit organizations
- Other: Dr. Schindler previously served as a sub-PI for the A4, DIAN-TU, and ENGAGE trials. Dr. Schindler participated in the IDEAS trial.

Diagnostic tests for AD



Amyloid PET



Cerebrospinal fluid biomarkers

Blood-based biomarkers

Two AD blood tests available for clinical use

- C2N Diagnostic's PrecivityAD test (IPMS plasma Aβ42/Aβ40 + apoE proteotype + age) https://precivityad.com
  - Several studies documenting assay performance have been published[1-4]
  - $1,250 but sliding scale available
- Quest's AD-Detect plasma Aβ42/Aβ40 ratio (IPMS plasma Aβ42/Aβ40) https://testdirectory.questdiagnostics.com/test/test-guides/TS_AD_Detect_BetaRatioPlasma/quest-ad-detect-beta-amyloid-4240-ratio-plasma
  - Plasma Aβ42/Aβ40 is less accurate by itself
  - No published studies of assay performance
  - $500
  - Available through Quest network of labs

[1]Kirmess *Clinica Chimica Acta* 2021
[2]West *Mol Neurodegen* 2021
[3]Hu *JAMA Open* 2022
[4]Schindler *Neurology* 2022

Removal of amyloid and slowing of cognitive decline



No. of Participants

Lecanemab	354	296	275	276	210
Placebo	344	303	286	259	205



No. of Participants

Lecanemab	859	824	798	779	765	738	714
Placebo	875	849	828	813	779	767	757

Van Dyck *NEJM* 2023

More to come?



Cummings *A&D* 2023